Clinical readout
BCMA T-cell engager velinotamig shows early activity in refractory lupus
Early results from an ongoing phase 1b/2a trial showed SLEDAI-2K dropped by four points or more in eight of the nine patients with refractory lupus who could be assessed. Four of seven with heavy baseline proteinuria reached complete renal response by week 24. Of 12 treated patients, two had low-grade cytokine release syndrome and none had dose-limiting toxicity.
- Drugvelinotamig
- TargetB-cell maturation antigen
- TargetT cell surface glycoprotein CD3
- TrialNCT07348055
- TrialNCT07738822
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.